ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).

被引：4
|
作者：
Armstrong, Andrew J.
Szmulewitz, Russell Zelig
Petrylak, Daniel Peter
Holzbeierlein, Jeffrey M.
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris Yakovlevich
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Baron, Benoit
Chen, Lucy F.
Stenzl, Arnulf
机构：
[1] Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
[4] Univ Kansas, Med Ctr, Westwood, KS USA
[5] Lille Univ, Univ Hosp Ctr, Dept Urol, Lille, France
[6] Monash Hlth, Melbourne, Vic, Australia
[7] Hosp Clin Barcelona, Dept Urol, Barcelona, Spain
[8] Hertzen Moscow Canc Res Inst, Moscow, Russia
[9] Osaka City Univ, Dept Urol, Grad Sch Med, Osaka, Japan
[10] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[11] Pfizer Inc, San Diego, CA USA
[12] Astellas Pharma Inc, Leiden, Netherlands
[13] Astellas Pharma Inc, Northbrook, IL USA
[14] Eberhard Karls Univ Tubingen, Univ Hosp, Dept Urol, Tubingen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5048
引用
收藏
页数：2
相关论文
共 50 条
  • [41] KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
    Gratzke, Christian
    Kwiatkowski, Mariusz
    Giorgi, Ugo De
    Martins da Trindade, Karine
    De Santis, Maria
    Armstrong, Andrew J.
    Niu, Cuizhen
    Liu, Yingjie
    Poehlein, Christian Heinrich
    FUTURE ONCOLOGY, 2022, 18 (37) : 4079 - 4087
  • [42] Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer A Randomized Clinical Trial
    Vaishampayan, Ulka N.
    Heilbrun, Lance K.
    Monk, Paul, III
    Tejwani, Sheela
    Sonpavde, Guru
    Hwang, Clara
    Smith, Daryn
    Jasti, Pallavi
    Dobson, Kimberlee
    Dickow, Brenda
    Heath, Elisabeth I.
    Semaan, Louie
    Cher, Michael L.
    Fontana, Joseph A.
    Chinni, Sreenivasa
    JAMA NETWORK OPEN, 2021, 4 (01) : E2034633
  • [43] Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) plus androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial.
    Armstrong, Andrew J.
    Iguchi, Taro
    Azad, Arun
    Szmulewitz, Russell Zelig
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Alcaraz, Antonio
    Alexeev, Boris
    Shore, Neal D.
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Zohren, Fabian
    Yamada, Shunsuke
    Haas, Gabriel P.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [44] First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO
    Rexer, H.
    Retz, M.
    Hammerer, P.
    UROLOGE, 2021, 60 (07): : 987 - 988
  • [45] Androgen deprivation therapy ± new antihormonal therapy for the treatment of metastatic hormone-sensitive prostate cancer
    Boegemann, Martin
    UROLOGIE, 2023, 62 (04): : 354 - 359
  • [46] Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): A systematic review of real-world database studies.
    Raval, Amit D.
    Chen, Stephanie
    Littleton, Natasha
    Constantinovici, Niculae
    Goebell, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 66 - 66
  • [47] A retrospective review of the benefits vs. safety implications of prednisolone during docetaxel chemotherapy alongside androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).
    Jameson, Molly
    Barker, Claire
    King, Jennifer
    Liang, Hui-Wen
    Carey, Charles
    Cripps, Nicole
    Jameson, Daisy
    Patel, Kamlesh
    Robinson, Andrew
    Hudson, Andrew
    Song, Yee Pei
    Conroy, Ruth
    Serra, Maria
    Choudhury, Ananya
    Logue, John
    Wylie, James
    Tran, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [48] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Tz, Melanie Go Spacing Diaeresis
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [49] EFFICACY AND FEASIBILITY OF ADDITIONAL CYCLES OF DOCETAXEL IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF UROLOGY, 2023, 209 : E388 - E389
  • [50] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Unterrainer, Lena
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345